Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine

Journal of Drug Targeting

Volumn 23, Issue 7-8, 2015, Pages 605-618

  Mattheolabakis, George ^a   Milane, Lara ^a   Singh, Amit ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

CD44 biology; CD44 HA targeting; drug delivery; hyaluronic acid; nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; HERMES ANTIGEN; HYALURONIC ACID; NANOCARRIER; NANOPARTICLE;

ARTICLE; BIODEGRADATION; BREAST CANCER; CANCER THERAPY; CHEMICAL MODIFICATION; CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; HUMAN; LUNG CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; NANOPARTICLES; NEOPLASMS;

EID: 84944235864     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1052072     Document Type: Article

References (121)

1. Jemal A, Siegel R, Xu JQ, Ward E. Cancer statistics, 2010. Ca-Cancer J Clin 2010;60:277-300
2. Stewart BW, Wild C. International Agency for Research on Cancer, World Health Organization. World cancer report 2014
3. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 2012;7: 1577-90
4. Dawidczyk CM, Russell LM, Searson PC. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem 2014;2: 1-13. doi: http://dx.doi.org/10.3389/fchem.2014.00069
5. Niitsu Y, Kohgo Y, Nishisato T, et al. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 1987;153:239-43
6. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-87
7. Tanaka T, Fujishima Y, Kaneo Y. Receptor mediated endocytosis and cytotoxicity of transferrin-mitomycin C conjugate in the HepG2 cell and primary cultured rat hepatocyte. Biol Pharm Bull 2001;24:268-73
8. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 2005;94:2135-46
9. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002;54: 675-93
10. Leamon CP, Low PS. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem 1992;267:24966-71
11. Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target 1994;2:101-12
12. Lee RJ, Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 1996;271:8481-7
13. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-41
14. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposomeentrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233: 134-44
15. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. ESMO 2004;15: 28-32
16. Schrevel M, Gorter A, Kolkman-Uljee SM, et al. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol 2011;24:720-8
17. Resnick NM, Clarke MR, Siegfried JM, et al. Expression of the cell adhesion molecule CD44 in human lung tumors and cell lines. Mol Diagn 1998;3:93-103
18. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73
19. Hiscox S, Baruha B, Smith C, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 2012;12:458
20. Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 2013;73: 4112-22
21. Gvozdenovic A, Arlt MJ, Campanile C, et al. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 2013;28:838-47
22. Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011;278:1429-43
23. Alshaer W, Hillaireau H, Vergnaud J, et al. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjug Chem 2014. [Epub ahead of print]. doi: 10.1021/bc5004313
24. Wang L, Su W, Liu Z, et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 2012;33:5107-14
25. Ndinguri MW, Zheleznyak A, Lauer JL, et al. Application of collagen-model triple-helical peptide-amphiphiles for CD44- targeted drug delivery systems. J Drug Deliv 2012;2012:592602
26. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45
27. Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal 2014;26:2234-9
28. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67
29. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 2011;9: 1573-86
30. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89:12160-4
31. Jiang H, Peterson RS, Wang W, et al. A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells. J Biol Chem 2002;277:10531-8
32. Foger N, Marhaba R, Zoller M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci 2001;114:1169-78
33. Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007;72:430-41
34. Hurt EM, Kawasaki BT, Klarmann GJ, et al. CD44 +CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Brit J Cancer 2008;98: 756-65
35. Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012;43:364-73
36. Nadella V, Wang Z, Johnson TS, et al. Transglutaminase 2 interacts with syndecan-4 and CD44 at the surface of human macrophages to promote removal of apoptotic cells. Biochim Biophys Acta 2015; 1853:201-12
37. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002;296:155-8
38. Miyatake Y, Sheehy N, Ikeshita S, et al. Anchorage-dependent multicellular aggregate formation induces CD44 high cancer stem cell-like ATL cells in an NF-kappaB- and vimentin-dependent manner. Cancer Lett 2015;357:355-63
39. Zhang P, Fu C, Bai H, et al. CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells. FEBS Lett 2014;588: 4573-82
40. Kiuchi S, Ikeshita S, Miyatake Y, Kasahara M. Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis. Exp Mol Pathol 2014;98:41-6
41. Hao J, Chen H, Madigan MC, et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Brit J Cancer 2010;103:1008-18
42. Bahnassy AA, Fawzy M, El-Wakil M, et al. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Transl Res 2015; 165:396-406
43. Chen Y, Fu Z, Xu S, et al. The prognostic value of CD44 expression in gastric cancer: a meta-analysis. Biomed Pharmacother 2014;68: 693-7
44. Heyse TJ, Malcherczyk D, Moll R, et al. CD44: survival and metastasis in chondrosarcoma. Osteoarthritis Cartilage 2010;18: 849-56
45. Wang Z, Shi Q, Gu Y, et al. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1alpha in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2011; 207:505-13
46. Robert L. Hyaluronan, a truly ''youthful'' polysaccharide. Its medical applications. Pathol Biol (Paris) 2015;63:32-4
47. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Vet Med-Czech 2008;53:397-411
48. Karbownik MS, Nowak JZ. Hyaluronan: towards novel anti-cancer therapeutics. Pharmacol Rep 2013;65:1056-74
49. Yaron M, Yaron I, Smetana O, et al. Hyaluronic acid produced by human synovial fibroblasts. Effect of polyinosinicpolycytidylic acid (poly I:C) and interferon. Arthritis Rheum 1976;19:1315-20
50. Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: a key molecule in skin aging. Dermatoendocrinol 2012;4:253-8
51. Spicer AP, Seldin MF, Olsen AS, et al. Chromosomal localization of the human and mouse hyaluronan synthase genes. Genomics 1997;41:493-7
52. Watanabe K, Yamaguchi Y. Molecular identification of a putative human hyaluronan synthase. J Biol Chem 1996;271:22945-8
53. Volpi N, Schiller J, Stern R, Soltes L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem 2009;16:1718-45
54. Fraser JR, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981;200:415-24
55. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001;20: 499-508
56. Jahn M, Baynes JW, Spiteller G. The reaction of hyaluronic acid and its monomers, glucuronic acid and N-acetylglucosamine, with reactive oxygen species. Carbohydr Res 1999;321:228-34
57. Kogan G, Soltes L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 2007;29:17-25
58. Chen WY, Abatangelo G. Functions of hyaluronan in wound repair. Wound Repair Regen 1999;7:79-89
59. Zhang LS, Mummert ME. Development of a fluorescent substrate to measure hyaluronidase activity. Anal Biochem 2008;379: 80-5
60. Underhill CB, Toole BP. Binding of hyaluronate to the surface of cultured cells. J Cell Biol 1979;82:475-84
61. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell Biol. 1990;2:839-44
62. Herrera-Gayol A, Jothy S. Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int J Exp Pathol 2001;82:193-200
63. Whatcott CJ, Han H, Posner RG, et al. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov 2011;1:291-6
64. Bertrand P, Girard N, Delpech B, et al. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer 1992;52:1-6
65. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem 2002;277:4585-8
66. Day AJ. The structure and regulation of hyaluronan-binding proteins. Biochem Soc Trans 1999;27:115-21
67. Arpicco S, De Rosa G, Fattal E. Lipid-based nanovectors for targeting of CD44-overexpressing tumor cells. J Drug Deliv 2013; 2013:860780
68. Knudson W, Chow G, Knudson CB. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002;21:15-23
69. Penno MB, August JT, Baylin SB, et al. Expression of CD44 in human lung tumors. Cancer Res 1994;54:1381-7
70. Wei HJ, Yin T, Zhu Z, et al. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment. Hepatobiliary Pancreat Dis Int 2011;10:428-34
71. Baumann M, Krause M. CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 2010;16:5091-3
72. Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 2008;10:35-42
73. Zhang H, Huang S, Yang X, Zhai G. Current research on hyaluronic acid-drug bioconjugates. Eur J Med Chem 2014;86C:310-17
74. Eliaz RE, Szoka Jr FC. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 2001;61:2592-601
75. Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013;34:3489-502
76. Ganesh S, Iyer AK, Weiler J, et al. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids 2013;2:e110
77. Price RD, Berry MG, Navsaria HA. Hyaluronic acid: the scientific and clinical evidence. JPRAS 2007;60:1110-19
78. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Current Opin Cell Biol 1994;6:726-33
79. Sironen RK, Tammi M, Tammi R, et al. Hyaluronan in human malignancies. Exp Cell Res 2011;317:383-91
80. Tian X, Azpurua J, Hine C, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013; 499:346-9
81. Schanté CE, Zuber G, Herlin C, Vandamme TF. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr Polym 2011;85:469-89
82. Prestwich GD, Marecak DM, Marecek JF, et al. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J Control Release 1998;53:93-103
83. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chem 1999; 10:755-63
84. Capodilupo A, Crescenzi V, Francescangeli A, et al. Hydrosoluble, metabolically fragile bioconjugates by coupling tetrabutylammonium hyaluronan with 20-paclitaxel-4-bromobutyrate: synthesis and antitumor properties. Hyaluronan 2003;1:391-5
85. Montagner IM, Banzato A, Zuccolotto G, et al. Paclitaxelhyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines. Urologic Oncol 2013;31: 1261-9
86. Banzato A, Bobisse S, Rondina M, et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008;14:3598-606
87. Bassi PF, Volpe A, D'Agostino D, et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol 2011;185:445-9
88. Campisi M, Renier D, Pierimarchi P, Serafino A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias. Google Patents. Publication number: WO 2009130564 A1, Application number: PCT/IB2009/005309; 2009
89. Serafino A, Zonfrillo M, Andreola F, et al. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets 2011;11:572-85
90. Tringali G, Bettella F, Greco MC, et al. Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat. J Pharmacy Pharmacol 2012;64:360-5
91. Xin D, Wang Y, Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. Pharmaceut Res 2010;27:380-9
92. Ma M, Chen H, Chen Y, et al. Hyaluronic acid-conjugated mesoporous silica nanoparticles: excellent colloidal dispersity in physiological fluids and targeting efficacy. J Mater Chem 2012;22: 5615-21
93. Yu M, Jambhrunkar S, Thorn P, et al. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 2013;5: 178-83
94. Chen Z, Li Z, Lin Y, et al. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery. Chemistry. 2013;19:1778-83
95. Surace C, Arpicco S, Dufay-Wojcicki A, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Molec Pharmaceut 2009;6:1062-73
96. Jiang T, Zhang Z, Zhang Y, et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012;33: 9246-58
97. Feng L, Liu Z. Graphene in biomedicine: opportunities and challenges. Nanomedicine 2011;6:317-24
98. Jung HS, Lee M-Y, Kong WH, et al. Nano graphene oxide- hyaluronic acid conjugate for target specific cancer drug delivery. RSC Advances 2014;4:14197-200
99. Lee J-E, In I, Lee H, et al. Target delivery and cell imaging using hyaluronic acid-functionalized graphene quantum dots. Molec Pharmaceut 2013;10:3736-44
100. Song E, Han W, Li C, et al. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery. ACS Appl Mater Inter 2014;6:11882-90
101. Li F, Park S-J, Ling D, et al. Hyaluronic acid-conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy. J Mater Chem B 2013;1:1678-86
102. Youngá Choi K, HyunáMin K, HeeáNa J, et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem 2009;19:4102-17
103. Choi KY, Chung H, Min KH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010;31: 106-14
104. Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013;65:1784-802
105. Li J, Huo M, Wang J, et al. Redox-sensitive micelles selfassembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012;33:2310-20
106. Singh A, Talekar M, Tran T-H, et al. Combinatorial approach in the design of multifunctional polymeric nano-delivery systems for cancer therapy. J Mater Chem B 2014;2:8069-84
107. Ganesh S, Iyer AK, Gattacceca F, et al. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release 2013;172:699-706
108. Yang X, Lyer AK, Singh A, et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep 2015;5:8509. doi: http://dx.doi.org/10.1038/srep08509
109. Yang X, Iyer AK, Singh A, et al. Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharmaceut Res 2015;32:2097-109
110. Song G, Liao X, Zhou L, et al. HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leukemia Res 2004;28:1089-96
111. Gadhoum Z, Delaunay J, Maquarre E, et al. The effect of anti- CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004; 45:1501-10
112. Stroomer JW, Roos JC, Sproll M, et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 2000; 6:3046-55
113. de Bree R, Roos JC, Quak JJ, et al. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995; 1:591-8
114. Colnot DR, Roos JC, de Bree R, et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeledhumanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003;52:576-82
115. Colnot DR, Ossenkoppele GJ, Roos JC, et al. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 2002;8:3401-6
116. Colnot DR, Quak JJ, Roos JC, et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000; 41:1999-2010
117. Postema EJ, Borjesson PK, Buijs WC, et al. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 2003;44: 1690-9
118. Borjesson PK, Postema EJ, Roos JC, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003;9:3961S-72S
119. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12:6064-72
120. Rupp U, Schoendorf-Holland E, Eichbaum M, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-cancer Drugs 2007;18:477-85
121. Riechelmann H, Sauter A, Golze W, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008;44: 823-9